中国2型糖尿病患者沙格列汀临床应用进展

Research on clinical application of Saxagliptin in Chinese type 2 diabetic patients

沙格列汀属于二肽基肽酶-4（DPP-4）抑制剂，此类药物是具有独特作用机制的治疗2型糖尿病的新型药物。大量临床研究证实，无论单药还是与其他降糖药物联合使用均可显著降低2型糖尿病患者的血糖，且不增加低血糖的风险。此外，大型心血管终点试验SAVOR研究证实沙格列汀不增加心血管死亡、非致死性心梗、非致死性缺血性卒中的主要心血管复合终点发生风险。

Saxagliptin belongs to the class of dipeptidyl peptidase-4 （DPP-4） inhibitors which are novel oral glucose-lowering agents with uniquely mechanism in patients with type 2 diabetes mellitus. Clinical efficacy without increasing hypoglycemia of saxagliptin as single agent as well as in combination with other medications used for the treatment of type 2 diabetes mellitus has been well established in several randomized trials. In addition, a cardiovascular outcome study of SAVOR shows that saxagliptin does not increase the risk of a composite of non-fatal myocardial infarction, non-fatal stroke or cardiovascular death meeting the primary safety objective. The efficacy and safety studies were hereby reviewed.